QM · rank #5 · 2026-07-23
LQDA
NASDAQ · $6.69B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +458.37% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +28.2% |
| Profit margin Net profit margin, trailing 12 months. | +7.7% |
| Market cap (USD) Size filter: > $500M required. | $6.69B |
| Anchor (recent) Close on 2026-06-23 | $74.04 |
| Anchor (far) Close on 2025-06-23 | $13.26 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Liquidia Technologies commercializes YUTREPIA, an FDA-approved dry-powder inhaled treprostinil, targeting PAH and PH-ILD patients as a differentiated alternative to United Therapeutics' Tyvaso franchise.
Rationale
The momentum_12_1 signal of 4.58 is directly reinforced by three consecutive profitable quarters, 44% sequential revenue growth in Q1 2026, and a 260%+ net income surge that validates the quality leg via positive ROE (0.28) and improving profit margins.
Material risks
- 1Single-product concentration in YUTREPIA means any safety signal, formulary exclusion, or aggressive Tyvaso DPI repricing could collapse the revenue base with no offsetting pipeline revenue for years given L606's early-stage status.
- 2Analyst consensus implies a meaningful sequential revenue step-down (~$110M vs. $129.9M Q1 actuals), suggesting the market may already be pricing in a pull-forward or one-time dynamic that could stall momentum if Q2 disappoints.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.